TransMedics Q2 Earnings Estimates Set to Disappoint
PorAinvest
lunes, 14 de julio de 2025, 12:29 am ET1 min de lectura
PIPR--
Analysts' ratings for TMDX have been mixed. Out of nine analysts, five have a "Buy" rating, four have a "Hold" rating, and zero have a "Sell" rating, reflecting a moderate buy consensus [1]. The top analysts, including TD Cowen, William Blair, and Piper Sandler, have reiterated their buy ratings, citing strong financial outlooks and robust revenue growth [1].
The average 12-month price target for TMDX is $135.29, with a high forecast of $170.00 and a low forecast of $103.00. This represents an average 20.30% upside from the last price of $112.46 [1]. Analysts at TD Cowen and Piper Sandler have the highest price targets at $170.00 and $145.00, respectively, while J.P. Morgan and Robert W. Baird have the lowest targets at $103.00 and $120.00, respectively [1].
TMDX's earnings forecast for the next quarter is $0.45, with a range of $0.34 to $0.59. The company has a strong track record of beating its earnings estimates, doing so 75.00% of the time in the past 12 months [1]. Sales forecasts for the next quarter are $146.74M, with a range of $144.00M to $150.00M, reflecting a 75.00% beat rate over the past year [1].
Despite the mixed analyst ratings, TMDX's financial performance and earnings beat rates suggest a company that is on the path to recovery. Investors should closely monitor the company's earnings reports and analyst updates to make informed decisions.
References:
[1] https://www.tipranks.com/stocks/tmdx/forecast
TMDX--
TransMedics has experienced a rollercoaster ride over the past year, with a 55% drop after Q3 2024 results that met management's expectations. However, the company's strong execution and trustworthiness have led to its recovery. Analyst estimates for Q2 are expected to be lower, but the company's solid performance suggests that it will continue to recover.
TransMedics Group (TMDX) has experienced a tumultuous journey over the past year, with a significant drop of 55% following Q3 2024 results that met management's expectations. However, the company's strong execution and trustworthiness have led to a recovery. Analyst estimates for Q2 are expected to be lower, but the company's solid performance suggests a continued recovery.Analysts' ratings for TMDX have been mixed. Out of nine analysts, five have a "Buy" rating, four have a "Hold" rating, and zero have a "Sell" rating, reflecting a moderate buy consensus [1]. The top analysts, including TD Cowen, William Blair, and Piper Sandler, have reiterated their buy ratings, citing strong financial outlooks and robust revenue growth [1].
The average 12-month price target for TMDX is $135.29, with a high forecast of $170.00 and a low forecast of $103.00. This represents an average 20.30% upside from the last price of $112.46 [1]. Analysts at TD Cowen and Piper Sandler have the highest price targets at $170.00 and $145.00, respectively, while J.P. Morgan and Robert W. Baird have the lowest targets at $103.00 and $120.00, respectively [1].
TMDX's earnings forecast for the next quarter is $0.45, with a range of $0.34 to $0.59. The company has a strong track record of beating its earnings estimates, doing so 75.00% of the time in the past 12 months [1]. Sales forecasts for the next quarter are $146.74M, with a range of $144.00M to $150.00M, reflecting a 75.00% beat rate over the past year [1].
Despite the mixed analyst ratings, TMDX's financial performance and earnings beat rates suggest a company that is on the path to recovery. Investors should closely monitor the company's earnings reports and analyst updates to make informed decisions.
References:
[1] https://www.tipranks.com/stocks/tmdx/forecast
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios